CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 41 enrolled
Drug / intervention
Aflibercept Injectiondrug
Likely dose
Aflibercept Injection 2mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04708145
NCT04708145Phase 4Completed
CompareCT.gov

Long-Term Efficacy and Safety of Intravitreal Aflibercept Injections for the Treatment of Diabetic Retinopathy for Subjects Who Completed the 2-Year PANORAMA Trial

Greater Houston Retina Research·interventional·Posted Jan 13, 2021·Updated Jan 23, 2025

In Brief

A Phase 4 clinical trial evaluating Aflibercept Injection for Diabetic Retinopathy. Completed, enrolled 41 participants across 14 sites in 2 countries.

Detailed Summary

The VOYAGE trial will assess diabetic retinopathy severity scale (DRSS) levels, through 112 weeks, while being managed with aflibercept as needed, among subjects who completed the 2-year PANORAMA trial (VGFTe-OD-1411) and were treated in a clinical setting prior to joining the VOYAGE study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetic Retinopathy
CountriesPuerto Rico, United States
CollaboratorsRegeneron Pharmaceuticals, Clinical Trials Resource Group, LLC

Timeline

Phase 4CompletedFinished
202120222023202420252026
First PostedJan 13, 2021
Enrollment StartJun 1, 2021
Primary CompletionJul 31, 2024
TodayJul 2, 2026
Enrollment to primary: 3.2 yearsPosted 5.5 years ago

Interventions

Aflibercept Injectiondrug

Intravitreal 2mg aflibercept injection